4-氨基-N-(6-氯-2-吡嗪基)苯磺酰胺钠盐
生物活性靶点体外研究体内研究
中文名称 | 4-氨基-N-(6-氯-2-吡嗪基)苯磺酰胺钠盐 |
---|---|
中文同义词 | 4-氨基-N-(6-氯-2-吡嗪基)苯磺酰胺钠盐;((4-氨基苯基)磺酰基)(6-氯吡嗪-2-基)酰胺钠;化合物 SULFACLOZINE SODIUM |
英文名称 | sodium N-(6-chloropyrazinyl)sulphanilamidate |
英文同义词 | sodium N-(6-chloropyrazinyl)sulphanilamidate;Sulfaclozine sodium monohydrate;4-Amino-N-(6-chloro-2-pyrazinyl)benzenesulfonamide sodium salt;Sodium ((4-aminophenyl)sulfonyl)(6-chloropyrazin-2-yl)amide;Sulfaclozine (sodium salt) |
CAS号 | 23307-72-4 |
分子式 | C10H10ClN4NaO2S |
分子量 | 308.72 |
EINECS号 | 245-571-9 |
相关类别 | |
Mol文件 | 23307-72-4.mol |
结构式 |
4-氨基-N-(6-氯-2-吡嗪基)苯磺酰胺钠盐 性质
储存条件 | under inert gas (nitrogen or Argon) at 2–8 °C |
---|---|
溶解度 | DMF:1mg/mL; DMSO:1mg/mL; PBS(pH 7.2):1 mg/mL |
形态 | 固体 |
颜色 | 浅黄至黄色 |
4-氨基-N-(6-氯-2-吡嗪基)苯磺酰胺钠盐 用途与合成方法
生物活性
Sulfaclozine sodium (Sulfachloropyrazine sodium) 是一种有效的磺酰胺衍生物,具有抗菌和抗球虫作用。Sulfaclozine sodium 通常用于各种家禽疾病(尤其是结肠杆菌病,禽霍乱和球虫病)的相关研究。
靶点
Bacterial; Parasite
体外研究
The elimination of Sulfaclozine in the three systems: UV/TiO 2 , UV/K 2 S 2 O 8 , and UV/TiO 2 /K 2 S 2 O 8 . Sulfaclozine is weakly adsorbed on the surface of TiO 2 at pH 7 (< 5%) but efficiently eliminated with the following three systems: UV/TiO 2 , UV/K 2 S 2 O 8 , and UV/TiO 2 /K 2 S 2 O 8 in ultra pure water. Moreover, 12 of Sulfaclozine by-products are identified and reaction pathways show that, in addition of • OH and SO 4 •− radicals, the conduction-band electrons are responsible for the formation of some main by-products either directly or by the formation of superoxide radicals.
体内研究
Sulfaclozine (60 mg/kg; intravenous injection or oral administration; male broiler chickens) can be used primarily for the treatment of parasitic and microbial infections of the digestive tract rather than for the treatment of systemic infections.
Animal Model: | 14 male broiler chickens (30-day-old) |
Dosage: | 60 mg/kg |
Administration: | Intravenous injection or oral administration (Pharmacokinetic Analysis) |
Result: | Serum drug concentrations at 0.083, 0.50, 2, 6, 24 and 72h were determined to be 99.62, 83.50, 72.68, 58.43, 38.66 and 13.14 μg/mL, respectively, by intravenous injection. By oral administration were determined as 4.33, 7.95, 16.46, 22.88, 16.03 and 5.74 μg/mL, respectively. |
安全信息
WGK Germany | 3 |
---|